Advanced Biomed (ADVB) declined roughly 48.8% over the trailing 30 days, sliding from about $5.14 to about $2.63 per share. The move extends a broader slide from a September 2026 peak near $10, with the stock down roughly two-thirds over the past quarter.
Veracyte (VCYT) shares fell roughly 45.5% over the last 30 days, driven by a sharp selloff after the company's third-quarter 2026 earnings report. The stock plunged about 54% in a single session after management reset growth expectations for its flagship Decipher Prostate test and trimmed forward guidance.
Exagen shares have dropped roughly 52% over the past 30 days, falling from about $8.42 on October 14, 2026, to around $4.05 intraday on November 13, 2026. The decline accelerated after third-quarter 2026 results, which showed a wider-than-expected loss and a sharp slowdown in AVISE CTD test-volume growth.
The central $0.75 stock price target is the arithmetic mean of the two verified, current analyst price targets we identified — $0.50 from Lake Street and $1.00 from TD Cowen — not a published consensus figure. With the stock trading around $0.15 (roughly $0.146), reaching $0.75 would require an increase of roughly 400%, an extremely large move even for a small-cap diagnostics name.
Third quarter 2026 revenue from continuing operations was $22.7 million, essentially flat versus the prior-year period. Operating loss widened to $8.1 million from $4.4 million a year earlier, while net loss per share came in at $0.19.
Innovation-led volume growth is the central forward theme, with the inVue Dx analyzer, Cancer Dx multi-cancer panel, and Catalyst ProBNP cardiac test forming a broad product cycle that management and analysts see as still in its early stages. Software and AI (artificial intelligence) are emerging as a second growth engine. The acquisition of CoVet, an AI clinical assistant, extends the ezyVet and Vello ecosystem and links diagnostics utilization to practice workflow.
The central target of $780 is the average of four verified analyst price targets that sit above the current share price, reflecting how far bullish analysts think IDEXX Laboratories (IDXX) can climb. As of the November 11, 2026 close, IDXX traded at $702.59, meaning the stock would need to rise roughly 11% to reach $780.
IDEXX Laboratories shares climbed roughly 35% over the past 30 days, rising from about $520 to above $700. The advance was driven primarily by a stronger-than-expected third-quarter earnings report and a raised full-year outlook announced in early November.
QUCY fell roughly 48% over the last 30 days, from about $1.12 (October 13) to approximately $0.58 (November 12). The decline extends a longer downtrend, with shares down roughly 60% over the trailing three months.
GRAL dropped -6.06% during regular market hours, sliding from a previous close of $125.64 to $118.03. No verified news or fundamental catalyst found. The decline is likely consistent with the stock's habitual high volatility — its typical daily move is roughly ±4.6%, and 13 of the past 60 sessions posted larger swings than today's.
IDEXX Laboratories (IDXX) shares advanced roughly 35% over the trailing 30 days, rising from about $520 to around $703. The move was driven primarily by a third-quarter beat-and-raise: on November 2, 2026, the stock jumped roughly 22% in a single session after results topped estimates and full-year guidance was lifted.
The central target of $33 is the arithmetic mean of five current analyst price targets, which range from $30 to $35. The latest verified close was $10.02 (November 10, 2026), so reaching $33 would require upside of roughly 229%.
Biodesix (BDSX) shares have dropped roughly 57% over the last 30 days, sliding from about $25.70 to near $11 per share. The bulk of the decline came in a single session after third-quarter 2026 revenue missed expectations and management cut full-year guidance.
The central target of $1.00 is the arithmetic mean of the remaining verifiable analyst price targets on record, which span a wide $0.50 to $1.50 range. With shares near $0.14, reaching $1.00 would require a gain of more than 600%, a very large move that reflects how sharply MDxHealth SA (MDXH) has fallen over the past year.
MDxHealth (MDXH) shares fell roughly 77% over the last 30 days, dropping from about $0.60 to approximately $0.14, after the company pre-announced disappointing third-quarter revenue and suspended its full-year guidance. The sharpest decline occurred in mid-October, when preliminary Q3 2026 revenue of $22.7 million fell short of expectations and triggered heavy selling volume.
The central $34 target is not an analyst-derived average; it reflects a publicly discussed technical milestone — a return to and modest reclaim of PRPO's 52-week high near $33.63 — because the company lacks current, credible analyst price targets. With shares near $25, reaching $34 requires a roughly 35% advance, a very large move for a single name.
The central $10.50 price target is the arithmetic mean of seven current analyst price targets, which average $10.57 across a range of $9 to $12. At a recent price near $5.32 after a sharp post-earnings sell-off, reaching $10.50 would require roughly a 97% advance — a very large move.
Exagen reported third quarter 2026 revenue of $18.4 million , up 7% year over year and slightly ahead of analyst consensus estimates. GAAP net loss per share was $0.25 , a wider loss than the roughly $0.19 analysts had expected.
The central target of $18 is the arithmetic mean of four verified analyst price targets, spanning a range of $17 to $21. With the stock near $10.57, reaching $18 implies a required upside of roughly 70%, a very large move for a recently listed company.
ICLR is the largest pure-play contract research organization (CRO), while IQV pairs clinical research with a large healthcare data and analytics franchise. IQV has delivered stronger, accelerating revenue growth in recent quarters and guided to mid-single-digit expansion for 2026.